Stockreport

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders [Yahoo! Finance]

Alterity Therapeutics Limited - American Depositary Shares  (ATHE) 
PDF – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker analysis advance understanding of MSA diagnos [Read more]